Patents by Inventor Louise Rodino-Klapac

Louise Rodino-Klapac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adeno-associated virus vector delivery of microRNA-29 and micro-dystrophin to treat muscular dystrophy
    Patent number: 11406717
    Abstract: The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from dystrophinopathy or muscular dystrophy. The invention also provides for combination therapies comprising expressing both miR-29 and micro-dystrophin to reduce and prevent fibrosis in patients suffering from dystrophinopathy or muscular dystrophy.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 9, 2022
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell, Kristin N. Heller
  • Adeno-associated virus vector delivery of B-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
    Patent number: 11358993
    Abstract: Described herein are recombinant AAV vectors comprising a polynucleotide sequence comprising ?-sarcoglycan and methods of using the recombinant vectors to reduce or prevent fibrosis in a mammalian subject suffering from a muscular dystrophy. Also described herein are combination therapies comprising administering AAV vector(s) expressing ?-sarcoglycan and miR-29c to a mammalian subject suffering from a muscular dystrophy.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: June 14, 2022
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell
  • Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy
    Patent number: 11298429
    Abstract: The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: April 12, 2022
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell, Kristin N. Heller
  • SYSTEMIC DELIVERY OF ADENO-ASSOCIATED VIRUS VECTOR EXPRESSING GAMMA-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHY
    Publication number: 20220088123
    Abstract: Described herein are methods of treating muscular dystrophy comprising administering a recombinant AAV (rAAV) scAAVrh74.MHCK7.hSGCG vector, methods of expressing gamma-sarcoglycan gene in a patient, pharmaceutical compositions comprising the rAAV, and methods of generating the rAAV.
    Type: Application
    Filed: September 7, 2021
    Publication date: March 24, 2022
    Inventors: Louise RODINO-KLAPAC, Eric POZSGAI
  • ADENO-ASSOCIATED VIRUS ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20220033478
    Abstract: The present disclosure relates to an isolated anti-AAV (adeno-associated virus) antibody or an antigen-binding fragment thereof capable of specifically binding an epitope of AAVrh74 capsid protein and uses thereof.
    Type: Application
    Filed: September 17, 2021
    Publication date: February 3, 2022
    Inventors: Sohrab KHAN, Danielle GRIFFIN, Louise RODINO-KLAPAC
  • Adeno-Associated Virus Vector Delivery for Muscular Dystrophies
    Publication number: 20210393801
    Abstract: The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subject's immune system.
    Type: Application
    Filed: June 15, 2021
    Publication date: December 23, 2021
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell, Ellyn Peterson, Rachael Potter, Danielle Griffin
  • ADENO-ASSOCIATED VIRUS ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20210388064
    Abstract: The present disclosure relates to an isolated anti-AAV (adeno-associated virus) antibody or an antigen-binding fragment thereof capable of specifically binding an epitope of AAVrh74 capsid protein and uses thereof.
    Type: Application
    Filed: June 15, 2021
    Publication date: December 16, 2021
    Inventors: Sohrab KHAN, Danielle GRIFFIN, Louise RODINO-KLAPAC
  • ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MUSCLE SPECIFIC MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY
    Publication number: 20210260218
    Abstract: The invention provides gene therapy vectors, such as adeno-associated vims (AAV) vectors, expressing a miniaturized human micro-dystrophin gene and method of using these vectors to express micro-dystrophin in skeletal muscle s including diaphragm and cardiac muscle and to protect muscle fibers from injury, increase muscle strength and reduce and/or prevent fibrosis in subjects suffering from muscular dystrophy.
    Type: Application
    Filed: June 17, 2019
    Publication date: August 26, 2021
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell
  • ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MUSCLE SPECIFIC MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY
    Publication number: 20210128749
    Abstract: The invention provides gene therapy vectors, such as adeno-associated vims (AAV) vectors, expressing a miniaturized human micro-dystrophin gene and method of using these vectors to express micro-dystrophin in skeletal muscle including diaphragm and cardiac muscle and to protect muscle fibers from injury, increase muscle strength and reduce and/or prevent fibrosis in subjects suffering from muscular dystrophy.
    Type: Application
    Filed: March 16, 2018
    Publication date: May 6, 2021
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell
  • ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MUSCLE SPECIFIC MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY
    Publication number: 20200199621
    Abstract: The invention provides gene therapy vectors, such as adeno-associated virus (AAV) vectors, expressing a miniaturized human micro-dystrophin gene and method of using these vectors to express micro-dystrophin in skeletal muscle s including diaphragm and cardiac muscle and to protect muscle fibers from injury, increase muscle strength and reduce and/or prevent fibrosis in subjects suffering from muscular dystrophy.
    Type: Application
    Filed: March 16, 2018
    Publication date: June 25, 2020
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell
  • ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND MICRORNA-29 AND THE TREATMENT OF MUSCULAR DYSTROPHY
    Publication number: 20190202880
    Abstract: Described herein are recombinant AAV vectors comprising a polynucleotide sequence comprising ?-sarcoglycan and methods of using the recombinant vectors to reduce or prevent fibrosis in a mammalian subject suffering from a muscular dystrophy. Also described herein are combination therapies comprising administering AAV vector(s) expressing ?-sarcoglycan and miR-29c to a mammalian subject suffering from a muscular dystrophy.
    Type: Application
    Filed: April 14, 2017
    Publication date: July 4, 2019
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell
  • ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRORNA-29 TO TREAT MUSCULAR DYSTROPHY
    Publication number: 20190117795
    Abstract: The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.
    Type: Application
    Filed: April 14, 2017
    Publication date: April 25, 2019
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell, Kristin N. Heller
  • ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRORNA-29 AND MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY
    Publication number: 20190060489
    Abstract: The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from dystrophinopathy or muscular dystrophy. The invention also provides for combination therapies comprising expressing both miR-29 and micro-dystrophin to reduce and prevent fibrosis in patients suffering from dystrophinopathy or muscular dystrophy.
    Type: Application
    Filed: April 14, 2017
    Publication date: February 28, 2019
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell, Kristin N. Heller
  • ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY
    Publication number: 20190055581
    Abstract: The invention provides for recombinant AAV vectors comprising a miniaturized human micro-dystrophin gene and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.
    Type: Application
    Filed: April 14, 2017
    Publication date: February 21, 2019
    Inventors: Louise Rodino-Klapac, Jerry R Mendell
  • RECOMBINANT ADENO-ASSOCIATED VIRUS DELIVERY OF ALPHA-SARCOGLYCAN POLYNUCLEOTIDES
    Publication number: 20190000998
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 3, 2019
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • Materials and Methods for Treatment of Titin-Based Myopathies and other Titinopathies
    Publication number: 20180360921
    Abstract: The present application provides materials and methods for treating a patient with a titin-based myopathy, particularly a titin-based cardiomyopathy, and/or other titinopathy. In addition, the present application provides materials and methods for editing the titin gene in a cell by genome editing.
    Type: Application
    Filed: November 15, 2016
    Publication date: December 20, 2018
    Inventors: Louise Rodino-Klapac, Rachael Potter
  • METHODS OF TREATING MUSCULAR DYSTROPHY
    Publication number: 20180340187
    Abstract: The invention provides for AAV vectors expressing the ANO5 gene and antioxidant therapy as methods of inducing muscle regeneration and a method of treating muscular dystrophy.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 29, 2018
    Applicant: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventor: Louise Rodino-Klapac
  • Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
    Patent number: 10105453
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: October 23, 2018
    Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • RECOMBINANT ADENO-ASSOCIATED VIRUS DELIVERY OF ALPHA-SARCOGLYCAN POLYNUCLEOTIDES
    Publication number: 20170209598
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Application
    Filed: September 2, 2016
    Publication date: July 27, 2017
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston
  • Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
    Patent number: 9434928
    Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: September 6, 2016
    Assignee: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Jerry R. Mendell, Louis Chicoine, Louise Rodino-Klapac, Kelly Reed Clark, Thomas J. Preston